
In the CONNECT trial, CGM users with type 2 diabetes not on insulin saw larger A1C reductions and more time in range than those using finger-stick testing.
Two studies evaluating the efficacy and long-term safety of the inhalable, rapid-acting dry powder insulin formulation (Exubera, Pfizer/Aventis) demonstrate that the drug was able to sustain glycemic control and pulmonary function in patients with type 2 diabetes






